SQ-LIP-000002 · v1.2 (archived) · View current version →
How common is lipedema, and who does it affect?
Based on currently indexed evidence, lipedema affects predominantly women and presents almost exclusively in females across every clinical cohort reviewed (U.S., German, Swiss, Italian, Brazilian, and Saudi samples), as well as in multiple reviews. Male occurrence is rare but documented (a case series of 5 men, isolated case reports, and consensus endorsement); obesity is described as a principal aggravating factor in both sexes. Symptom onset is most commonly linked to periods of hormonal change — puberty (reported in ~48–62% of patients across cohorts), pregnancy (~22–41%), and less often menopause; an autosomal-dominant inheritance pattern with female preference has been proposed. True population prevalence remains poorly defined. The most consistent figures come from clinical/lymphology settings and reviews: a systematic review compiled estimates of ~11% in women (Földi), ~15% (Herpertz), and 18.8% of 843 patients with lower-limb enlargement, with lymphology-clinic prevalence reported at 6.5–18.8%. A Saudi cross-sectional study clinically confirmed lipedema in 71% of 115 patients with lower-limb edema. A Brazilian screening-based study estimated probable lipedema at ~12.3% of adult women, but this relies on self-reported questionnaires without clinical confirmation, carries a low evidence grade, and was endorsed with the lowest agreement in a 2025 consensus — likely an overestimate of clinically diagnosed disease. These prevalence estimates are drawn largely from low-grade reviews, case reports, and clinic-based (selection-biased) samples, so population incidence and true prevalence remain undetermined. Clinical cohort data describe a condition of middle adulthood (mean ages ~38–49 years), with first manifestation typically in adolescence and prolonged diagnostic delay (mean ~15 years in one German cohort). Underrecognition is striking: 77% of confirmed Saudi patients were previously undiagnosed, and a cited UK study found 93% of patients with lipedema signs/symptoms were unrecognized by their physicians. Family history is reported by roughly 16–64% of patients across sources (~46–50% in larger cohorts), suggesting a heritable component of undetermined genetic background. Lipedema is not exclusive to overweight/obese women (documented persisting in a woman with BMI 15 kg/m²), and it carries substantial comorbidity burden including hypothyroidism, depression, chronic venous disease, and reduced quality of life across multiple independent cohorts.
Knowledge freshness = share of the 17 indexed evidence sources from the last 5 years (newest 2025, oldest 2012) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
This update added multiple reviews and cross-sectional studies (notably a systematic review and a moderate-grade Saudi cohort) providing additional, convergent prevalence estimates (~11% in women, 6.5–18.8% in lymphology clinics, 71% clinically confirmed), reinforcing the BMI-dependent lymphedema gradient, and documenting profound underrecognition (77–93% undiagnosed) plus persistence at low BMI.
Supporting claims
- SCR-LIP-000012 supporting
The estimated prevalence of probable lipedema among adult Brazilian women is approximately 12.3%, indicating a common rather than rare condition.
Prevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) - SCR-LIP-000138 supporting
This systematic review reports lipedema prevalence estimates of 11% in women (Földi), 15% of patients in a lymphology clinic (Herpertz), and 18.8% of 843 patients with lower-limb enlargement, occurring almost exclusively in women, with positive family history in 16–64% of cases.
Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome – systematic review — Forner‐Cordero et al. (2012) - SCR-LIP-000141 supporting
In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed.
Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024) - SCR-LIP-000142 supporting
Lipedema is a chronic disorder presenting almost exclusively in women, typically beginning during periods of hormonal change such as puberty, childbirth, or menopause, with an autosomal dominant inheritance pattern showing female preference and reported prevalence in lymphology clinics of 6.5–18.8%.
Lipedema: friend and foe — Torre et al. (2018)
Contradictory claims
- None indexed yet.
Refining / context
- SCR-LIP-000014 context
Lipedema occurs in men with the classical phenotype (bilateral, symmetrical, foot-sparing lower-limb fat accumulation, negative Stemmer sign), although it almost exclusively affects women and male occurrence is rare.
Lipedema in Men: A Retrospective Case Series of Five Patients From a Brazilian Referral Center — Amato et al. (2025) · Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) - SCR-LIP-000076 context
In a national survey of 707 U.S. women with lipedema, the mean age was 48.6 years and mean BMI was 40.9 kg/m², with symptom onset most commonly at puberty (48.0%) or pregnancy (41.2%), and the condition exclusively affected women in this sample.
National survey of patient symptoms and therapies among 707 women with a lipedema phenotype in the United States — Aday et al. (2024) - SCR-LIP-000077 context
In a survey of 209 German female lipedema patients who underwent liposuction, the average age was 38.5 years, first manifestation occurred at age 16, and diagnosis took a mean of 15 years to achieve, with comorbidities including hypothyroidism (35.9%) and depression (23.0%) at rates exceeding general population prevalence.
New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat — Bauer et al. (2019) - SCR-LIP-000078 context
Lipedema is a serious disease with undetermined genetic background that affects women, first described as a syndrome in 1940, and is neither a cosmetic problem nor a lifestyle issue, though its true prevalence and incidence remain poorly defined in the literature.
Lipedema Research—Quo Vadis? — Ernst et al. (2022) - SCR-LIP-000079 context
In a retrospective series of 106 lipedema patients who underwent liposuction, the cohort was exclusively female with a median BMI of 31.6 kg/m², and showed elevated prevalence of obesity, hypothyroidism, migraine, and depression compared to non-lipedema populations, while diabetes (5%) and dyslipidemia (7%) prevalence were unexpectedly low.
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis — Ghods et al. (2020) - SCR-LIP-000080 context
In a Swiss referral centre cohort of 381 women with lipedema (mean age 41.9 years), 49.9% reported a family history, 62.2% reported symptom onset during adolescence, and 92.1% had comorbidities, with pain affecting 87.9% and significantly reduced quality of life in the majority.
Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025) - SCR-LIP-000081 context
In a cohort of 360 Italian women with lipedema of the lower limbs (stages 1–3), the condition was found exclusively in women and was associated with comorbidities including vitamin D insufficiency, chronic venous disease, dyslipidemia, depression, and higher-than-expected prevalence of autoimmune thyroiditis and polycystic ovary syndrome.
Observational Study on a Large Italian Population with Lipedema: Biochemical and Hormonal Profile, Anatomical and Clinical Evaluation, Self-Reported History — Patton et al. (2024) - SCR-LIP-000139 context
This case report of a 53-year-old male with lipedema notes that lipedema is less frequent in men than in women, that obesity is the principal aggravating factor in both sexes, and that the authors' case series detects lymphedema by multi-segment bioimpedance in 50% of individuals with lipedema and BMI above 30 kg/m2.
Lipedema in Male Progressing to Subclinical and Clinical Systemic Lymphedema — Pereira de Godoy et al. (2022) - SCR-LIP-000140 context
This case report cites epidemiological data estimating lipedema prevalence at approximately 11% of the female population, predominantly affecting women, and reports a UK study finding 93% of patients with lipedema signs/symptoms were unrecognized by their physicians; it also describes lipedema persisting in a woman with low BMI (15 kg/m²), demonstrating it is not exclusive to overweight/obese women.
A Young Woman with Excessive Fat in Lower Extremities Develops Disordered Eating and Is Subsequently Diagnosed with Anorexia Nervosa, Lipedema, and Hypermobile Ehlers-Danlos Syndrome — Wright & Herbst (2021) - SCR-LIP-000143 context
This systematic review of lipedema pathology notes that lipedema is a symmetrically localized, painful hypertrophy of subcutaneous adipose tissue in the extremities that almost exclusively affects females.
Auf der Suche nach der Evidenz: Eine systematische Übersichtsarbeit zur Pathologie des Lipödems — Funke et al. (2023) - SCR-LIP-000144 context
In a cross-sectional study of 258 women with clinically diagnosed lipedema stratified by BMI, the prevalence of lower-limb clinical lymphedema rose from 6.1% (BMI <30) to 51.6% (BMI 30-40) to 77.8% (BMI 40-50), and subclinical systemic lymphedema from 16.3% to 48.3% to 72.2%, with a dose-response gradient by BMI.
Lipedema and the Evolution to Lymphedema With the Progression of Obesity — Pereira de Godoy et al. (2020)
Major uncertainty
True population-based prevalence and incidence remain undetermined: the available estimates (~11% of women, 6.5–18.8% in lymphology clinics, ~12.3% Brazilian screening, 71% clinically confirmed in a Saudi edema cohort) derive from low-grade reviews, case reports, and selection-biased clinic samples or unconfirmed self-report questionnaires, with no high-quality general-population study. The genetic basis of the heritable component and the wide range in reported family history (16–64%) also remain unresolved.
Version history
- SQ-LIP-000002 · v1.2 — 2026-05-31 — This update added multiple reviews and cross-sectional studies (notably a systematic review and a moderate-grade Saudi cohort) providing additional, convergent prevalence estimates (~11% in women, 6.5–18.8% in lymphology clinics, 71% clinically confirmed), reinforcing the BMI-dependent lymphedema gradient, and documenting profound underrecognition (77–93% undiagnosed) plus persistence at low BMI. · view this version
- SQ-LIP-000002 · v1.1 — 2026-05-31 — This update substantially expanded the epidemiological and demographic profile of lipedema by adding seven new context claims from large clinical cohorts (U.S., German, Swiss, Italian) and a scoping review, providing consistent data on age of onset, diagnostic delay, family history, reproductive milestone triggers, comorbidity burden, and quality of life impairment — none of which were present in the prior answer. · view this version
- SQ-LIP-000002 · v1.0 — 2026-05-30 — founding index (15 claims) · view this version
Key references
DOI:10.1590/1677-5449.202101981 · DOI:10.1590/1677-5449.202301832 · DOI:10.7759/cureus.87332 · DOI:10.1177/1358863x231202769 · DOI:10.1097/prs.0000000000006280 · DOI:10.3390/jpm13010098 · DOI:10.1111/dth.14534 · DOI:10.1371/journal.pone.0319099 · DOI:10.3390/ijms25031599 · DOI:10.1111/j.1758-8111.2012.00045.x · DOI:10.14740/jmc3806 · DOI:10.12659/ajcr.930840 · DOI:10.1097/gox.0000000000006173 · DOI:10.1515/hmbci-2017-0076 · DOI:10.1055/a-2183-7414 · DOI:10.7759/cureus.11854